Triumvira Immunologics to Present Clinical Data at the 2024 ASCO Gastrointestinal Cancers Symposium

December 19, 2023

Austin, TX, Hamilton, ON and South San Francisco, CA – Dec. 19, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will present two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco, California, from January 18-20, 2024. The company will showcase clinical data from its ongoing Phase I/II studies investigating the safety and efficacy of autologous TAC-T cells targeting human epidermal growth factor receptor 2 (HER2) and Claudin 18.2 (CLDN 18.2), respectively, in relapsed or refractory solid tumors (TACTIC-2 /NCT04727151, TACTIC-3 /NCT05862324).

The technology behind TAC01-HER2 and TAC01-CLDN18.2 stands as an innovative cell-based therapeutic modality, harnessing genetically engineered T cells derived autologously. These T cells are equipped with a T-cell Antigen Coupler (TAC) rationally designed to specifically recognize HER2 or CLDN18.2 within tumor cells.